CALN1 hypomethylation as a biomarker for high-risk bladder cancer.

Kimiaki TakagiAzumi NaruseKazutoshi AkitaYuka Muramatsu-MaekawaKota KawaseTakuya KoieMasanobu HorieArizumi Kikuchi

Published in: BMC urology (2022)

Our findings suggest that CALN1 methylation percentage could be a useful molecular biomarker for bladder cancer.

Keyphrases